Shilpa Medicare has announced a strategic partnership between Steincare and Shilpa Biologicals to enhance biosimilar access across Latin American markets. This collaboration marks a significant expansion initiative for the pharmaceutical sector in the region.

Strategic Partnership Details

The partnership agreement between Steincare and Shilpa Biologicals focuses on improving the availability and accessibility of biosimilar products throughout Latin America. This strategic alliance combines the expertise and resources of both organizations to address the growing demand for affordable biosimilar medications in the region.

Market Expansion Initiative

The deal represents a focused effort to strengthen pharmaceutical presence in Latin American markets. By joining forces, the two entities aim to leverage their combined capabilities to better serve healthcare needs across multiple countries in the region. This partnership is positioned to enhance the distribution and availability of biosimilar products, potentially improving patient access to essential medications.

Regional Healthcare Impact

The collaboration is expected to contribute to the broader healthcare landscape in Latin America by expanding access to biosimilar treatments. This initiative aligns with ongoing efforts to improve pharmaceutical accessibility and affordability across emerging markets, particularly in the biosimilar segment which offers cost-effective alternatives to biological medicines.

Shilpa Medicare Limited has issued a revised disclosure regarding its strategic partnership with NXI Therapeutics AG, following terminology updates requested by the University for alignment with an upcoming high-impact journal publication. The revised disclosure, dated 14 February 2026, clarifies specific wording related to the novel asset and therapy descriptions.

Revised Disclosure Details

The company informed stock exchanges that NXI Therapeutics requested updates to maintain consistency between the partnership announcement and a forthcoming scientific publication. The revisions specifically address terminology for the "novel asset" and "novel therapy" to treat autoimmune or alloimmune disorders.

Partnership Framework

The strategic collaboration with NXI Therapeutics AG, a Switzerland-based biotechnology company, remains unchanged in its core structure. Under the binding agreement, Shilpa Medicare will provide comprehensive development and manufacturing services for a New Chemical Entity targeting autoimmune and alloimmune disorders.

Strategic Context

This partnership represents the third major international development and manufacturing contract secured by Shilpa group in recent months, demonstrating strengthening demand from Western biotech companies for its integrated R&D capabilities and advanced GMP manufacturing infrastructure.

Management Statements

Mr. Vishnukanth Bhutada, Managing Director, Shilpa Medicare Limited, commented: "This collaboration reinforces Shilpa's transformation into a strategic innovation partner for global biotech companies. Our integrated development and commercial manufacturing capabilities enable us to support complex assets across the full product lifecycle."

Dr. Ruben Herrendorff, CEO, NXI Therapeutics AG, added: "Shilpa's scientific depth, quality systems, and scalable GMP manufacturing capabilities make them an ideal partner as we advance our immunomodulatory program toward clinical and commercial milestones."

Company Profiles

Shilpa Medicare Limited operates as a global pharmaceutical company and integrated CDMO providing end-to-end solutions across small molecules, biologics, and complex therapeutics. NXI Therapeutics is a Swiss biotechnology company focused on developing safe immunotherapies for autoimmune and alloimmune conditions through targeted immunomodulation that preserves immunocompetence.